Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Co. (UK) Ltd. as Sole Book-Running Manager of Viking Therapeutics’ $24.0M IPO
New York, NY – May 6, 2015 – New York City based securities and corporate law firm Sichenzia Ross Friedman Ference LLP (the “Firm”) announced today that the Firm has represented Laidlaw & CO. (UK) Ltd. as the sole book-running manager of the initial public offering (IPO) of Viking Therapeutics, Inc. (NASDAQ: VKTX). The public offering consisted of 3,000,000 shares of the Company’s common stock at a price to the public of $8.00 per share which resulted in aggregate gross proceeds of $24,000,000 before deducting expenses. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The Sichenzia Ross Friedman Ference LLP team was led by Partners Richard A. Friedman and Stephen A. Cohen.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Partner Benjamin Tan Joins China Internet Nationwide Financial Services, Inc. in Ringing the Closing Bell at Nasdaq MarketSite - August 17, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar and Fordham Financial Management in $11.8 PIPE financing of Aytu Bioscience, Inc. - August 16, 2017
- Sichenzia Ross Ference Kesner LLP Represents Vuzix Corporation in $8.6 Million Registered Direct Offering - August 16, 2017